Cesar E. Bogado

TL;DR: The ISCD Official Positions for quantitative computed tomography (QCT) and peripheral QCT (pQCT), with supporting medical evidence, rationale, controversy, and suggestions for further study are presented.

TL;DR: The data suggest that structural decay owing to bone remodeling and progression of bone fragility may be prevented more effectively with denosumab.

TL;DR: Once‐daily administration of teriparatide induced beneficial changes in the structural architecture of the distal radial diaphysis consistent with increased mechanical strength without adverse effects on total bone mineral density or cortical bone mineral content.

TL;DR: Denosumab reduced remodeling more rapidly and completely than alendronate, reduced porosity of the three cortical regions at 6months, more so by 12months relative to baseline and controls, and 1.5- to 2-fold more so than alendedronate.

TL;DR: In conclusion, teriparatide treatment improved axial and bending strength, and increased cortical thickness and stability at the femoral neck and intertrochanteric region in postmenopausal women enrolled in the Fracture Prevention Trial.